Tonix Pharmaceuticals (NASDAQ: TNXP) announced financial results for the third quarter ended Sept. 30, 2026, reporting net product revenue of approximately $17.2 million, compared with $3.3 million in the prior-year period. Revenue included $15 million from TONMYA, representing a 37% increase over the second quarter. Total prescriptions rose 28% quarter over quarter to 16,375, while new prescriptions increased 17% and refills climbed 56%. TONMYA coverage expanded to approximately 166 million lives, and the company increased its sales force to approximately 150 representatives. Tonix reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32 million, or $3.59 per share, a year earlier.
Tonix ended the quarter with approximately $163 million in cash and cash equivalents and expects its resources, together with approximately $1.5 million in subsequent equity financing proceeds, to fund operations into early third-quarter 2027. The company continues to advance its clinical pipeline, including the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention. The latter two studies are expected to begin in the first quarter of 2027, with the TNX-4800 study pending final U.S. Food and Drug Administration agreement on its protocol.
To view the full press release, visit https://ibn.fm/xRQdn
Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN